The short version of reversed-phase HPLC fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-03-05. Anything still debated is marked as such rather than presented as settled.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Typical form for short synthetic peptides |
| Solubility class | Freely soluble in water and aqueous buffer | Dissolution aided by gentle mixing, not vigorous shaking |
| Typical storage temperature | −20 °C, desiccated | −80 °C used for long-term holding |
| Common analytical method | Reverse-phase HPLC with UV detection near 214 nm | Identity confirmed separately by mass spectrometry |
| Common synonyms | Thymosin beta-4 fragment; TB4 fragment | Naming varies between suppliers and publications |
Reconstitution of a lyophilized peptide is normally done with sterile water or a suitable buffer under aseptic conditions. Adding solvent down the vial wall and allowing gentle dissolution instead of vigorous vortexing reduces the chance of aggregation, which can lower the effective concentration of the resulting solution. Concentrated stocks are usually diluted into working buffer shortly before use. Because no standard preparation protocol exists for TB-500 specifically, laboratories adapt general peptide handling practice, and reported results may reflect differing preparation choices.
Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
Israel is one of only a few nations that conscript women or deploy them in combat roles. In practice, women can avoid conscription through a religious exemption and over a third of Israeli women do so. As of 2010, 88% of all roles in the IDF are open to female candidates, and women were found in 69% of all IDF positions. According to the IDF, 535 female Israeli soldiers were killed in combat operations in the period 1962–2016, and dozens before then. The IDF says that fewer than 4 percent of women are in combat positions. Rather, they are concentrated in "combat-support" positions which command a lower compensation and status than combat positions.
== Reactions == Acrolein is a relatively electrophilic compound and a reactive one, hence its high toxicity. It is a good Michael acceptor, hence its useful reaction with thiols. It forms acetals readily, a prominent one being the spirocycle derived from pentaerythritol, diallylidene pentaerythritol. Acrolein participates in many Diels-Alder reactions, even with itself. Via Diels-Alder reactions, it is a precursor to some commercial fragrances, including myrac aldehyde ("lyral") and norbornene-2-carboxaldehyde. The monomer 3,4-epoxycyclohexylmethyl-3',4'-epoxycyclohexane carboxylate is also produced from acrolein via the intermediacy of tetrahydrobenzaldehyde.
DNA repair The set of processes by which a cell identifies and corrects structural damage or mutations in the DNA molecules that encode its genome. The ability of a cell to repair its DNA is vital to the integrity of the genome and the normal functionality of the organism.
== Protein structure and Terminology == Proteins are chains of amino acids joined together by peptide bonds. Many conformations of this chain are possible due to the rotation of the main chain about the two torsion angles φ and ψ at the Cα atom. This conformational flexibility is responsible for differences in the three-dimensional structure of proteins.
Sources: en.wikipedia.org
== Applications == Variable pathlength techniques can be applied in any situation where Beer's law can be applied. It provides an analytical method that averages out minor variations in sample preparation consistency. It also provides a means to calculate concentrations without calibrations curves or serial dilution of samples. Variable pathlength absorption spectroscopy is typically used when highly reproducible data is a necessity. This can be in the fields of medicine, biotechnology, pharmacology, and drug discovery. It is particularly useful in the protein purification stage of biotechnology where accurate concentrations of various proteins are required or in crystallography. Determining the relative ratio of protein to DNA is common practice and can be calculated by finding the slope at the corresponding absorption peaks and taking their ratio. This method is used to find the purity of a sample containing these two types of molecule.
No significant changes in HbA1c were observed in the control group (Group B) between baseline (7.1%) and the end of the control lessons (7.0%). The number of 'hypos' decreased significantly from 31 to 14 in Group A (p = 0.03) after AIDA lessons, but did not change significantly in Group B from baseline (n = 20) to after the control lessons (n = 22). Full details of the study and the results can be found in the medical / diabetes literature. The study authors concluded that "larger trials involving more patients in more centres are clearly needed, but this proof-of-concept (pilot) study does demonstrate the feasibility of using a prospective randomised controlled trial approach for the evaluation of educational diabetes simulation software such as AIDA".
== Sources == Aristotle. Metaphysics Nicomachean Ethics On the Soul. Physics Caston, Victor. "Aristotle's Psychology". A Companion to Ancient Philosophy. Ed. Mary Gill and Pierre Pellegrin. Hoboken: Wiley-Blackwell, 2006. 316–46. "Aristotle's Two Intellects: A Modest Proposal". Phronesis 44.3 (1999): 199–227. Cross, Richard. The Physics of Duns Scotus. Oxford: Oxford UP, 1998. Eberl, Jason T. "Aquinas on the Nature of Human Beings." The Review of Metaphysics 58.2 (November 2004): 333–65. Gilson, Étienne. The Philosophy of St. Bonaventure. Trans. F. J. Sheed. NY: Sheed & Ward, 1938. Irwin, Terence. Aristotle's First Principles. Oxford: Oxford UP, 1990. Keck, David. Angels & Angelology in the Middle Ages. NY: Oxford UP, 1998. Kenny, Anthony. Aquinas on Mind. London: Routledge, 1993. Leftow, Brian. "Souls Dipped in Dust." Soul, Body, and Survival: Essays on the Metaphysics of Human Persons. Ed. Kevin Corcoran. NY: Cornell UP, 2001. 120–38. "Soul, Mind, and Brain." The Waning of Materialism. Ed. Robert C. Koons and George Bealer. Oxford: Oxford UP, 2010. 395–417. McEvilley, Thomas. The Shape of Ancient Thought. NY: Allworth, 2002. Mendell, Henry. "Aristotle and Mathematics". Stanford Encyclopedia of Philosophy. 26 March 2004. Stanford University. 2 July 2009 <http://plato.stanford.edu/entries/aristotle-mathematics/>. Normore, Calvin. "The Matter of Thought". Representation and Objects of Thought in Medieval Philosophy. Ed. Henrik Lagerlund. Hampshire: Ashgate, 2007. 117–133. Pasnau, Robert. Thomas Aquinas on Human Nature. Cambridge: Cambridge UP, 2001. Robinson, Timothy.
Sources: en.wikipedia.org
TB-500 is a trade-style label for a synthetic peptide connected to thymosin beta-4. It is sold mainly through research-chemical channels and is not a single chemically defined product across suppliers.
Not necessarily. Some vendors use the name for the full 43-residue protein, while others apply it to a short actin-binding fragment or to a related tetrapeptide. The sequence should be confirmed from documentation rather than assumed from the label.
No thymosin beta-4 fragment holds marketing approval as a medicine in major jurisdictions. Material offered for sale is typically labelled for laboratory research only.
The leading proposal involves sequestration of monomeric actin, which would alter cytoskeletal turnover and cell movement. The actin-binding motif shared with the parent protein is central to that idea. Direct confirmation in whole organisms remains limited.